Reference is made to the stock exchange announcement published on 3 December
2024 by EXACT Therapeutics AS (the "Company") regarding the successful placement
of new shares with gross proceeds of NOK 145 million (the "Private Placement"),
including that the Company may carry out a subsequent offering with non-tradable
subscription rights of up to 2,150,537 new shares and 921,658 non-tradable
warrants (the "Subsequent Offering"), depending inter alia on the development of
the price of the shares in the Company after completion of the Private
Placement.
Following announcement of the Private Placement, the Company's shares have
traded around or below the subscription price in the Private Placement at
volumes exceeding the size of the potential Subsequent Offering. Accordingly,
any shareholder wishing to reduce the dilutive effect of the Private Placement
have had sufficient opportunity to purchase shares in the Company in the market
at prices around, similar to or below what would have been the subscription
price in the Subsequent Offering. The issue of warrants has not changed this
assessment.
On this basis, the board of directors of the Company has today resolved not to
proceed with the Subsequent Offering.
For more information, please contact:
Per Walday, CEO
EXACT Therapeutics
Email per.walday@exact-tx.com
About EXACT-Tx:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound and microbubbles to enable targeted drug delivery in
oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be
applied to a wide range of therapeutic agents within oncology and across a
multitude of other indications including brain diseases.
www.exact-tx.com